Program - Society of Toxicology

Society of Toxicology 2011
Program Description (Continued)
Abstract #
#795 Poster Board Number.....................................921
SUBCHRONIC ORAL TOXICITY
EVALUATION OF CP31398, A P53
STABILIZER, IN DOGS. ​W. D. Johnson 1 , M.
Muzzio 1 , C. J. Detrisac 2 , L. Kopelovich 3 , I. M.
Kapetanovic 3 and D. L. McCormick 1 . 1 IIT Research
Institute, Chicago, IL, 2 Pathology Associates,
Chicago, IL and 3 National Cancer Institute, Bethesda,
MD.
#796 Poster Board Number.....................................922
SUBCUTANEOUS ADMINISTRATION
STUDY TO DETERMINE THE INFLUENCE
OF AN ANTI-MOUSE IL-12/IL-23P40
ANTIBODY ON PHOTOCARCINOGENESIS
IN HAIRLESS MICE. ​W. M. Bracken 1 , D. Learn 2 ,
G. Blaich 1 and G. M. Veldman 3 . 1 Global Preclinical
Safety, Abbott, Abbott Park, IL, 2 Photobiology, CRL,
Horsham, PA and 3 Biologics Generation, Abbott
Bioresearch Center, Worcester, MA.
#797 Poster Board Number.....................................923
ANTIBODY-MEDIATED VASCULITIS:
IN VIVO INVESTIGATIONS INTO THE
MECHANISM OF TOXICITY. ​K. Mackay 1 ,
T. Sullivan 1 , M. Carioto1, J. Senn 1 , J. Lane 2 , J. S.
Michaelson 3 and J. C. Clarke 1 . 1 Pharmacotoxicology,
Biogen Idec, Cambridge, MA, 2 Comparative
Pathology, Biogen Idec, Cambridge, MA and
3
Immunobiology, Biogen Idec, Cambridge, MA.
#798 Poster Board Number.....................................924
INHIBITION OF THE ENZYME
S-NITROSOGLUTATHIONE (GSNO)
REDUCTASE DOES NOT CAUSE
MECHANISM-BASED TOXICITY. ​D. B.
Colagiovanni, X. Sun, J. Qiu, A. Stout, A. Patton, L.
Green, J. Richards and G. J. Rosenthal. Research,
N30 Pharmaceuticals, Boulder, CO.
#799 Poster Board Number.....................................925
ORAL TWO WEEK (3X/WEEK) DOSE
RANGE FINDING STUDY OF DECITABINE
AND TETRAHYDROURIDINE IN CD-1
MICE. ​K. Engelke 1 , E. Hanan 1 , J. Covey 2 , Y.
Ling 3 , K. Chan 3 , Y. Saunthararajah 4 and P. Terse 2 .
1
AVANZA Laboratories, LLC, Gaithersburg, MD,
2
National Cancer Institute, Bethesda, MD, 3 Ohio
State University, Columbus, OH and 4 Cleveland
Clinic, Cleveland, OH.
#800 Poster Board Number.....................................926
CONSEQUENCES OF REPEATED
COMPLEMENT ACTIVATION AFTER
CHRONIC TREATMENT IN CYNOMOLGUS
MONKEYS. ​L. Shen 1 , T. Machemer 1 , P. Giclas 2
and S. Henry 1 . 1 ISIS Pharmaceuticals, Inc., Carlsbad,
CA and 2 National Jewish Health, Denver, CO.
#801 Poster Board Number.....................................927
SINGLE INTRACEREBROVENTRICULAR
INFUSION TOXICITY, TOXICOKINETICS,
AND DISTRIBUTION STUDY OF
TRIPEPTIDYL PEPTIDASE-1 IN
CYNOMOLGUS MONKEYS. ​B. Vuillemenot 1 ,
L. Tsuruda 1 , D. Kennedy 1 , D. Musson 1 , S. Keve 1 , R.
Reed 2 , R. Boyd 2 , M. Butt 3 and C. O’Neill 1 . 1 BioMarin
Pharmaceutical Inc., Novato, CA, 2 Northern
Biomedical Research, Inc., Muskegon, MI and
3
ToxPath Specialists, LLC, Hagerstown, MD.
Abstract #
#802 Poster Board Number.....................................928
THE SAFETY OF CBD IN SOCIAL ANXIETY
DISORDER PATIENTS. ​M. M. Bergamaschi 1,2 ,
M. Chagas 2 , D. Oliveira 2 , B. Martinis 3 , J. Hallak 2 ,
A. Zuardi 2 , J. Crippa 2 and R. Queiroz 1 . 1 School of
Pharmaceutical Science of Ribeirão Preto, University
of São Paulo, Ribeirão Preto, SP, Brazil, 2 School of
Medicine of Ribeirão Preto, University of São Paulo,
Ribeirão Preto, SP, Brazil and 3 School of Philosophy,
Science and Literature of Ribeirão Preto, University
of São Paulo, Ribeirão Preto, SP, Brazil.
#803 Poster Board Number.....................................929
IN VITRO MABEL APPROACH FOR
NONCLINICAL SAFETY ASSESSMENT
OF MEDI-565 (MT111), A NOVEL CEA/
CD3-BISPECIFIC SINGLE-CHAIN BITE
ANTIBODY. ​P. C. Ryan 1 , S. A. Hammond 1 , S.
Ren 1 , P. Lutterbuese 2 , M. Amann 2 , M. D. Oberst 1 ,
K. Mulgrew 1 , R. Criste 1 , S. Fuhrmann 1 , N. Lee 1 ,
R. Gross 1 , M. Liang 1 , A. Schneider 1 , R. Dixit 1 , P.
A. Baeuerle 2 , B. Rattel 2 , S. Coats 1 , L. Roskos 1 , K.
Bosslet 1 , B. Jallal 1 and L. Richman 1 . 1 MedImmune,
Gaithersburg, MD and 2 Micromet, Bethesda, MD.
#804 Poster Board Number.....................................930
HEAT SHOCK PROTEIN 90 INHIBITORS
CAN INDUCE VISUAL CHANGES AND
RETINAL DEGENERATION INCLUDING
IRREVERSIBLE PHOTORECEPTOR LOSS
IN DOGS. ​V. Torti 1 , J. Marcek 3 , K. Muravnick 3 ,
S. Aguirre 1 , J. Fortner 3 , J. Render 3 , T. Schmahai 3 ,
S. Yamazaki 2 , L. Nguyen 2 , Z. Shen 2 and L. Burns-
Naas 1 . 1 DSRD, Pfizer Inc., La Jolla, CA, 2 PDM,
Pfizer Inc., La Jolla, CA and 3 DSRD, Pfizer Inc.,
Groton, CT.
#805 Poster Board Number.....................................931
BIOEQUIVALENCY OF TWO DIFFERENT
METHOTREXATE FORMULATIONS IN
HEPATIC GENE EXPRESSION OF PXB-
MOUSE ® WITH HIGHLY HUMANIZED
LIVER. ​M. Nakashima 1 , H. Tachiki 2 , T. Shimada 3 ,
D. Hynes 4 and S. Nagatsuka 4 . 1 Graduate School of
Biomedical Sciences, Nagasaki University, Nagasaki,
Japan, 2 Research & Development Division, Towa
Pharmaceutical Co., Ltd., Kadoma, Osaka, Japan,
3
PhoenixBio Co., Higashi-Hiroshima, Hiroshima,
Japan and 4 R&D, Sekisui Medical Co., ADME &
Toxicology Research Institute, Tokai-mura, Ibaraki,
Japan. Sponsor: T. Miyaoka.
#806 Poster Board Number.....................................932
PRECLINICAL ASPECTS OF BIOSIMILAR
DEVELOPMENT – PRACTICAL
CONSIDERATIONS. ​P. Baldrick and R.
Donninger. Covance Laboratories Ltd., Harrogate,
United Kingdom. Sponsor: S. Kirk.
#807 Poster Board Number.....................................933
THE INCIDENCE OF TOXICOKINETIC
CONTROL SAMPLE CONTAMINATION IN
REGULATORY TOXICOLOGY STUDIES. ​S.
Cahill and R. Turcan. Covance Laboratories Ltd.,
Harrogate, United Kingdom. Sponsor: S. Kirk.
MONday
Poster Sessions
Regional Interest Session
Roundtable Sessions
Symposium Sessions
Thematic Sessions
Workshop Sessions
183